Entering text into the input field will update the search result below

PMN:CA ProMIS Neurosciences, Inc.
Stock Price & Overview

$6.00-0.24 (-3.85%)4:00 PM 07/21/23
TSX | $CAD | Market Close


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Ratings Summary

SA Analysts
Wall Street

See PMN:CA ratings with Premium.

People Also Follow

Company Profile

ProMIS Neurosciences, Inc. logo
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
  • 1920 Yonge Street
  • Suite 200
  • Toronto, ON, M4S 3E2
  • Canada
Phone Number
416 847 6898
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.